PharmAthene to Present at The Maxim Group Growth Conference September 29, 2009
ANNAPOLIS, Md., Sept. 23 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the Maxim Group Growth Conference 2009. The Company is scheduled to present on Tuesday, September 29(th) 2009 at 11:00 a.m. E.T. in the Imperial Room at the Grant Hyatt Hotel, New York City.
PharmAthene's presentation will be webcast live and will be archived for 90 days. The webcast can be accessed at: http://www.wsw.com/webcast/maxim2/pip/
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
Third generation rPA anthrax vaccine
Valortim((R))-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Protexia((R)) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
RypVax(TM) -- a recombinant dual antigen vaccine for plague
